激肽释放酶基因在子痫前期患者中的表达及活性变化

目的:了解激肽释放酶基因表达与子痫前期发生、发展的关系。方法:用逆转录-聚合酶链反应(RT-PCR)及酶底物S2266分别检测子痫前期轻、重度患者共30例及30例正常孕妇(对照组)胎盘中激肽释放酶基因表达及尿液中激肽释放酶活性的差异。结果:与对照组相比,子痫前期患者胎盘中激肽释放酶mRNA的表达水平及尿液中激肽释放酶活性明显降低(P<0.01);而且子痫前期重度患者的上述指标较子痫前期轻度患者更低(P<0.05)。结论:激肽释放酶基因表达缺陷或抑制与子痫前期的发生、发展以及病情轻重相关。

Changes of kallikrein(KK) gene expression and activity in pre-eclampsia patients

Objective:To evaluate expression and activity of kallikrein in gravida with pre-eclampsia.Methods:Three groups were set as normal(30 cases),mild pre-eclampsia group(7 cases) and severe pre-eclampsia group(23 cases).RT-PCR and S2266 was used to detect the expression of kallikrein mRNA in placenta and activity in urine respectively.Results:Expression level of kallikrein mRNA in placenta and the activity in urine from pre-eclampsia patients were significantly lower than those in control group(P<0.01).And in severe pre-eclampsia group,expression of kallikrein mRNA in placenta and activity in urine were also lower than those in mild group(P<0.05).Conclusion:The repression and absence expression of kallikrein are related to the severity of pre-eclampsia and may be involved in the development of this disease.